



Palivizumab

Revised: December 3, 2018.

CASRN: 188039-54-5

Drug Levels and Effects

Summary of Use during Lactation

No information is available on the clinical use of palivizumab during breastfeeding. Because palivizumab is a large protein molecule with a molecular weight of about 148,000, the amount in milk is likely to be very low and absorption is unlikely because it will probably be destroyed in the infant's gastrointestinal tract.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Identification

Substance Name

Palivizumab

CAS Registry Number

188039-54-5

Drug Class

Breast Feeding

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site .

Lactation

Antibodies, Monoclonal

Antiviral Agents